Followers | 150 |
Posts | 2303 |
Boards Moderated | 0 |
Alias Born | 01/24/2012 |
Sunday, July 19, 2020 7:01:41 PM
Moleculin has a unique opportunity to contribute to the global challenge posed by coronavirus and other viruses threatening our communities. We recently announced a collaboration with a major Texas university institution to evaluate our drug candidate, WP1122, and its analogs and this has now been followed by collaborations with additional players who bring the needed expertise to fully develop this new potential treatment for diseases like COVID-19.
Independent researchers at the Institute of Biochemistry II – Goethe-Universität Frankfurt in Germany recently announced their discovery that 2-DG, the active compound in WP1122, reduced in vitro replication of SARS-CoV-2 by 100%.
We now have a very strong reason to believe that WP1122 may be effective against COVID-19. This is based on the vital roles that glucose plays in the proliferation of SARS-CoV-2. Viruses like SARS-CoV-2 place increased demand on glucose and upregulate their host cell’s metabolic processes. Some of the most important of these processes are believed to be glycolysis and glycosylation.
Recent MBRX News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/07/2024 12:30:19 PM
- Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024 • PR Newswire (US) • 10/07/2024 12:30:00 PM
- Moleculin to Present at Two Upcoming Investor Conferences • PR Newswire (US) • 10/04/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2024 08:30:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/23/2024 12:00:16 PM
- Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma • PR Newswire (US) • 09/23/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 12:31:07 PM
- Moleculin Participates in Virtual Investor "What this Means" Segment • PR Newswire (US) • 09/16/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 12:15:29 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/13/2024 08:15:24 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/13/2024 08:04:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 12:15:12 PM
- Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma • PR Newswire (US) • 09/09/2024 12:15:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 09/03/2024 09:15:55 PM
- Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference • PR Newswire (US) • 09/03/2024 01:15:00 PM
- Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar • PR Newswire (US) • 08/26/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 08:10:01 PM
- Moleculin Announces Closing of up to $16.5 Million Public Offering • PR Newswire (US) • 08/19/2024 08:05:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/19/2024 02:06:59 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 08/16/2024 08:54:18 PM
- Moleculin Announces Pricing of up to $16.5 Million Public Offering • PR Newswire (US) • 08/16/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/16/2024 04:15:15 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/15/2024 03:21:01 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/15/2024 01:57:37 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:05:24 PM
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM